摘要
我国胃癌患者基数大、病期晚、预后差,5年总体生存率仅有35.1％.新技术、新药物和新设备的涌现为改善我国胃癌患者的预后提供了新的契机.组学技术拓展了胃癌分子分型认知,为胃癌生物标志物指导下的精准治疗提供了支持.针对高度微卫星不稳定型患者,围手术期免疫治疗提供了非手术管理的潜在可能.微创技术具有与开放手术相当的长期预后结果,腹腔镜技术可作为Ⅰ～Ⅲ期胃癌患者的常规手术方式.淋巴结的清扫需考虑肿瘤位置、肿瘤大小及侵犯深度.跨学科交叉融合有助于进一步推动胃癌治疗的精准化.
Abstract
In China,gastric cancer has a large population base,most patients are diagnosed on late-stage and with poor prognosis,5-year overall survival rate is only 35.1％The emergence of new technologies,drugs,and equipment provides new opportunities to improve the prognosis of gastric cancer.Omics technologies have expanded our understanding of molecular subtypes in gastric cancer,supporting biomarker-guided precision treatment.For MSI-H patients,perioperative immunotherapy offers potential non-surgical management options.Minimally invasive techniques have shown long-term prognosis results comparable to open surgery,with laparoscopic technology becoming a routine surgical approach for stage Ⅰ-Ⅲ gastric cancer patients.Lymph node dissection should consider tumor location,size,and depth of invasion.Interdisciplinary integration helps to further promote precision treatment of gastric cancer.
NETL
NSTL
万方数据